ERBB2 and gastroesophageal junction adenocarcinoma: Results from the DESTINY-Gastric06 trial demonstrated clinically meaningful antitumor activity for T-DXd in patients from China with HER2+ advanced gastric or GEJ adenocarcinoma whose disease had progressed after two or more prior anticancer regimens.